Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH) : final evidence report Tice, Jeffrey A., author. Fahim, Shahariar Mohammed, author. Richardson, Marina, author. Herce-Hagiwara, Belen, author. Chu, Janet N., author. Pearson, Steven D., author. Rind, David M., author. Suh, Kangho, author. Carlson, Josh, author. Dickerson, Ronald, author. Chenodeoxycholic Acid -- analogs & derivatives Liver Cirrhosis -- drug therapy Non-alcoholic Fatty Liver Disease -- drug therapy Pyridazines Uracil -- analogs & derivatives Two oral medications are currently being evaluated as treatments for NASH with fibrosis. Resmetirom (RES) is a small molecule agonist for the thyroid hormone receptor beta (THR-beta). Obeticholic Acid (OCA) is a bile acid analog that was approved for the treatment of patients with primary biliary cholangitis (PBC) in 2016. Topline data from a phase 3 trial found that more patients treated with resmetirom 80 mg or 100 mg than placebo had ≥ 1 stage improvement in fibrosis without worsening of NASH (24% and 26% vs. 14%) and more had NASH resolution without worsening of fibrosis (26% and 30% vs. 10%). The most frequent adverse event was diarrhea (28% to 34% vs. 16% placebo); LDL-cholesterol decreased with resmetirom compared with placebo.4 More patients treated with OCA 25 mg for 18 months than placebo had achieved ≥ 1 stage improvement in fibrosis without worsening of NASH (22% vs. 10%) without significant differences between groups in NASH resolution without worsening of fibrosis. [Boston, Massachusetts] : Institute for Clinical and Economic Review, May 25, 2023 Institute for Clinical and Economic Review, issuing body. Midwest Comparative Effectiveness Public Advisory Council, issuing body. Technical Report Text Illustrations 1 online resource (1 PDF file (various pagings)) nlm:nlmuid-9918697384206676-pdf 9918697384206676 http://resource.nlm.nih.gov/9918697384206676 English United States Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. http://creativecommons.org/licenses/by/4.0